338 related articles for article (PubMed ID: 19804814)
1. Obesity and corticosteroids: 11beta-hydroxysteroid type 1 as a cause and therapeutic target in metabolic disease.
Morton NM
Mol Cell Endocrinol; 2010 Mar; 316(2):154-64. PubMed ID: 19804814
[TBL] [Abstract][Full Text] [Related]
2. Glucocorticoids and 11beta-hydroxysteroid dehydrogenase type 1 in obesity and the metabolic syndrome.
Stimson RH; Walker BR
Minerva Endocrinol; 2007 Sep; 32(3):141-59. PubMed ID: 17912154
[TBL] [Abstract][Full Text] [Related]
3. Inhibition of 11beta-hydroxysteroid dehydrogenase type 1 as a promising therapeutic target.
Wamil M; Seckl JR
Drug Discov Today; 2007 Jul; 12(13-14):504-20. PubMed ID: 17631244
[TBL] [Abstract][Full Text] [Related]
4. 11β-Hydroxysteroid dehydrogenase type 1: relevance of its modulation in the pathophysiology of obesity, the metabolic syndrome and type 2 diabetes mellitus.
Pereira CD; Azevedo I; Monteiro R; Martins MJ
Diabetes Obes Metab; 2012 Oct; 14(10):869-81. PubMed ID: 22321826
[TBL] [Abstract][Full Text] [Related]
5. Is the metabolic syndrome an intracellular Cushing state? Effects of multiple humoral factors on the transcriptional activity of the hepatic glucocorticoid-activating enzyme (11beta-hydroxysteroid dehydrogenase type 1) gene.
Iwasaki Y; Takayasu S; Nishiyama M; Tsugita M; Taguchi T; Asai M; Yoshida M; Kambayashi M; Hashimoto K
Mol Cell Endocrinol; 2008 Mar; 285(1-2):10-8. PubMed ID: 18313835
[TBL] [Abstract][Full Text] [Related]
6. 11Beta-hydroxysteroid dehydrogenase type 1 in human disease: a novel therapeutic target.
Tomlinson JW
Minerva Endocrinol; 2005 Mar; 30(1):37-46. PubMed ID: 15877012
[TBL] [Abstract][Full Text] [Related]
7. Tissue production of cortisol by 11beta-hydroxysteroid dehydrogenase type 1 and metabolic disease.
Walker BR; Andrew R
Ann N Y Acad Sci; 2006 Nov; 1083():165-84. PubMed ID: 17148739
[TBL] [Abstract][Full Text] [Related]
8. 11beta-hydroxysteroid dehydrogenase type 1 inhibitors for metabolic syndrome.
Schnackenberg CG
Curr Opin Investig Drugs; 2008 Mar; 9(3):295-300. PubMed ID: 18311666
[TBL] [Abstract][Full Text] [Related]
9. 11beta-hydroxysteroid dehydrogenase type 1 and obesity.
Morton NM; Seckl JR
Front Horm Res; 2008; 36():146-164. PubMed ID: 18230901
[TBL] [Abstract][Full Text] [Related]
10. Diet and the role of 11beta-hydroxysteroid dehydrogenase-1 on obesity.
London E; Castonguay TW
J Nutr Biochem; 2009 Jul; 20(7):485-93. PubMed ID: 19443197
[TBL] [Abstract][Full Text] [Related]
11. 11 beta-hydroxysteroid dehydrogenase type 1 in obesity and the metabolic syndrome.
Wake DJ; Walker BR
Mol Cell Endocrinol; 2004 Feb; 215(1-2):45-54. PubMed ID: 15026174
[TBL] [Abstract][Full Text] [Related]
12. Type 2 diabetes and metabolic syndrome are associated with increased expression of 11beta-hydroxysteroid dehydrogenase 1 in obese subjects.
Alberti L; Girola A; Gilardini L; Conti A; Cattaldo S; Micheletto G; Invitti C
Int J Obes (Lond); 2007 Dec; 31(12):1826-31. PubMed ID: 17593901
[TBL] [Abstract][Full Text] [Related]
13. Cortisol--cause and cure for metabolic syndrome?
Walker BR
Diabet Med; 2006 Dec; 23(12):1281-8. PubMed ID: 17116176
[TBL] [Abstract][Full Text] [Related]
14. 11beta-hydroxysteroid dehydrogenase type 1 as a modulator of glucocorticoid action: from metabolism to memory.
Seckl JR; Walker BR
Trends Endocrinol Metab; 2004 Nov; 15(9):418-24. PubMed ID: 15519888
[TBL] [Abstract][Full Text] [Related]
15. Inhibitors of 11β-hydroxysteroid dehydrogenase type 1 in antidiabetic therapy.
Wang M
Handb Exp Pharmacol; 2011; (203):127-46. PubMed ID: 21484570
[TBL] [Abstract][Full Text] [Related]
16. Is 11beta-hydroxysteroid dehydrogenase type 1 a therapeutic target? Effects of carbenoxolone in lean and obese Zucker rats.
Livingstone DE; Walker BR
J Pharmacol Exp Ther; 2003 Apr; 305(1):167-72. PubMed ID: 12649365
[TBL] [Abstract][Full Text] [Related]
17. Regulation of 11beta-HSD genes in human adipose tissue: influence of central obesity and weight loss.
Engeli S; Böhnke J; Feldpausch M; Gorzelniak K; Heintze U; Janke J; Luft FC; Sharma AM
Obes Res; 2004 Jan; 12(1):9-17. PubMed ID: 14742837
[TBL] [Abstract][Full Text] [Related]
18. 11beta-Hydroxysteroid dehydrogenase type 1 inhibitors: novel agents for the treatment of metabolic syndrome and obesity-related disorders?
Anagnostis P; Katsiki N; Adamidou F; Athyros VG; Karagiannis A; Kita M; Mikhailidis DP
Metabolism; 2013 Jan; 62(1):21-33. PubMed ID: 22652056
[TBL] [Abstract][Full Text] [Related]
19. Overexpression of hepatic 5α-reductase and 11β-hydroxysteroid dehydrogenase type 1 in visceral adipose tissue is associated with hyperinsulinemia in morbidly obese patients.
Baudrand R; Domínguez JM; Carvajal CA; Riquelme A; Campino C; Macchiavello S; Bozinovic M; Morales M; Pizarro M; Solis N; Escalona A; Boza C; Arrese M; Fardella CE
Metabolism; 2011 Dec; 60(12):1775-80. PubMed ID: 21704348
[TBL] [Abstract][Full Text] [Related]
20. 11beta-hydroxysteroid dehydrogenase and the pre-receptor regulation of corticosteroid hormone action.
Draper N; Stewart PM
J Endocrinol; 2005 Aug; 186(2):251-71. PubMed ID: 16079253
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
